GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ESSA Pharma Inc (NAS:EPIX) » Definitions » Net Cash per Share

ESSA Pharma (ESSA Pharma) Net Cash per Share : $3.13 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is ESSA Pharma Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). ESSA Pharma's Net Cash per Share for the quarter that ended in Dec. 2023 was $3.13.

The historical rank and industry rank for ESSA Pharma's Net Cash per Share or its related term are showing as below:

EPIX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.49   Med: 2.17   Max: 73.58
Current: 1.99

During the past 10 years, the highest Price-to-Net-Cash Ratio of ESSA Pharma was 73.58. The lowest was 0.49. And the median was 2.17.

EPIX's Price-to-Net-Cash is ranked better than
73.18% of 865 companies
in the Biotechnology industry
Industry Median: 4.19 vs EPIX: 1.99

ESSA Pharma Net Cash per Share Historical Data

The historical data trend for ESSA Pharma's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ESSA Pharma Net Cash per Share Chart

ESSA Pharma Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.30 2.40 4.34 3.74 3.28

ESSA Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.63 3.51 3.38 3.28 3.13

Competitive Comparison of ESSA Pharma's Net Cash per Share

For the Biotechnology subindustry, ESSA Pharma's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ESSA Pharma's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ESSA Pharma's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where ESSA Pharma's Price-to-Net-Cash falls into.



ESSA Pharma Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

ESSA Pharma's Net Cash per Share for the fiscal year that ended in Sep. 2023 is calculated as

Net Cash per Share (A: Sep. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(148.076-3.495-0)/44.1008
=3.28

ESSA Pharma's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(142.12-3.806-0)/44.1637
=3.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ESSA Pharma  (NAS:EPIX) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


ESSA Pharma Net Cash per Share Related Terms

Thank you for viewing the detailed overview of ESSA Pharma's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ESSA Pharma (ESSA Pharma) Business Description

Traded in Other Exchanges
N/A
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
Executives
Peter Virsik officer: Chief Operating Officer 131 ESCANYO WAY, PORTOLA VALLEY CA 94028
David Ross Parkinson director, officer: Chief Executive Officer C/O THRESHOLD PHARMACEUTICALS, INC., 170 HARBOR WAY SUITE 300, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Lauren Merendino director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David S. Wood officer: Chief Financial Officer 3516 WEST 33RD AVE, VANCOUVER A1 V6N 2H4
Biotech Growth N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Philip W. Kantoff director 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104